• Kymera outlined a strategy to build an oral targeted protein degradation pipeline in immunology, aiming for biologics-like activity with pill convenience.
• Lead program KT-621, an oral STAT6 degrader, is positioned as a potential alternative to dupilumab across Type 2 inflammatory diseases.
• KT-621 Phase 2b atopic dermatitis readout targeted by mid-2027; Phase 2b asthma data targeted in late 2027.
• Second core program KT-579, an oral IRF5 degrader, targets lupus and other autoimmune diseases; Phase 1 healthy-volunteer data expected in 2H26.
• Presentation highlighted a large immunology market, citing more than $100 billion in annual sales for advanced therapies and low penetration of systemic options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.